EMA Authorised: Mvabea (recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP) — Janssen-Cilag International N.V.

View source ↗

Summary

EMA authorised Mvabea, a recombinant Modified Vaccinia Ankara-based vaccine developed by Janssen-Cilag International N.V., for prevention of Ebola virus disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease
• Marburg Virus Disease

Drugs mentioned

• Mvabea

Snippet

Status: Authorised. Therapeutic area: Hemorrhagic Fever, Ebola. MAH: Janssen-Cilag International N.V.. Decision date: 26/03/2025